Presentation on Thursday, November 21st at 12:25pm ET DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it will present at the PCG Spotlight Series Conference taking place on Thursday, November 21st at the… Read More..

- Exicure to Receive $25 Million Upfront Payment and Up to $725 Million in potential Milestones - Exicure to Host Conference Call Today at 8:30am ET/7:30am CT CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc., (XCUR) a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that Allergan’s… Read More..

CHICAGO & CAMBRIDGE, Mass.-- (BUSINESS WIRE) --Exicure, Inc. (XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced that David Giljohann, chief executive officer Exicure, Inc. (XCUR), has been named to Crain’s Chicago Business magazine’s 2019 Class of “40 Under 40.” Crain’s “40… Read More..